ASX Linkedin Twitter               

 

Scientific Presentations 2016

 

Presentation Title Conference Date
A phase Ib study of intratumoral CAVATAK (coxsackievirus A21) and ipilimumab in patients with advanced melanoma Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting National Harbor MD, USA 12 November 2016
A combination study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: phase Ib KEYNOTE 200 (STORM study) Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting National Harbor MD, USA 12 November 2016
Interim results of the CAPRA clinical trial: CAVATAK and pembrolizumab in advanced melanoma Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting National Harbor MD, USA 12 November 2016
Poster
Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical Coxsackievirus A21

Presentation by Dr Annels
Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical Coxsackievirus A21
Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting National Harbor MD, USA 11 November 2016
Phase II CALM extension study: intratumoral CAVATAK™ increases immune-cell infiltrates and up-regulates immune-checkpoint molecules in the microenvironment of lesions from advanced melanoma patients Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting National Harbor MD, USA 12 November 2016
1051PD – The MITCI (phase 1b) study: A novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma European Society for Medical Oncology (ESMO) Annual Conference, Copenhagen, Denmark 10 October 2016
1054PD – Phase I/II CANON study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21 European Society for Medical Oncology (ESMO) Annual Conference, Copenhagen, Denmark 10 October 2016
1157TiP – Phase Ib study of intratumoral oncolytic coxsackievirus A21 (CVA21) and pembrolizumab in subjects with advanced melanoma European Society for Medical Oncology (ESMO) Annual Conference, Copenhagen, Denmark 9 October 2016
1104TiP – Intravenous coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: Phase Ib KEYNOTE 200 study European Society for Medical Oncology (ESMO) Annual Conference, Copenhagen, Denmark 9 October 2016
Phase I/II CANON study: Oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder (NMIBC) Cancer using Intravesical Coxsackievirus A21 Oncolytic Virus Conference, 10th International Meeting, Vancouver, Canada 4 October 2016
Phase II CALM Extension study: Intratumoral Coxsackievirus A21 increases immune-cell infiltrates and up-regulates immune-checkpoint molecules in the micoenvironment Oncolytic Virus Conference, 10th International Meeting, Vancouver, Canada 3 October 2016
Pre-clinical investigation of CAVATAK™ (Coxsackievirus A21) as a potential treatment for pancreatic cancer Oncolytic Virus Conference, 10th International Meeting, Vancouver, Canada 3 October 2016
Phase I/II CANON study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21 – Hardev S Pandha MD PhD 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago 4-6 June 2016
Phase I STORM study (KEYNOTE 200): Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients – Hardev S Pandha MD PhD 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago 5 June 2016
(8.00am – 11.30am)
Hall A – Poster Board #423b
Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21 – Robert Andtbacka MD CM 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago 4 June 2016
(1.00pm – 4.30pm)
Hall A – Poster Board #158
Elevated immune activity following an anticancer combination therapy of a novel oncolytic immunotherapeutic agent, CAVATAK (Coxsackievirus A21), and immune checkpoint blockade American Association for Cancer Research Annual Meeting, New Orleans, USA  16 – 20 April 2016
Intratumoral Coxsackievirus A21 increases immune-cell infiltrates and up-regulates immune-checkpoint molecules in the tumor microenvironment of advanced melanoma patients: Phase II CALM Extension study American Association for Cancer Research Annual Meeting, New Orleans, USA  16 – 20 April 2016
Phase 1b study of a novel immunotherapy combination therapy of intralesional Coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma American Association for Cancer Research Annual Meeting, New Orleans, USA  16 – 20 April 2016
Phase I/II CANON study: Oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder Cancer using intravesical CAVATAK (Coxsackievirus A21) Annual EAU Conference, Munich, Germany  11 – 15 March 2016

 

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).